Cargando…

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria

BACKGROUND: Chimeric antigen receptor T-cell therapy (CART) prolongs survival for patients with refractory or relapsed lymphoma. Discrepancies among different response criteria for lymphoma under CART were recently shown. Our objective was to evaluate reasons for discordance among different response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winkelmann, Michael, Blumenberg, Viktoria, Rejeski, Kai, Bücklein, Veit L., Ingenerf, Maria, Unterrainer, Marcus, Schmidt, Christian, Dekorsy, Franziska J., Bartenstein, Peter, Ricke, Jens, von Bergwelt-Baildon, Michael, Subklewe, Marion, Kunz, Wolfgang G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184388/ https://www.ncbi.nlm.nih.gov/pubmed/37189191 http://dx.doi.org/10.1186/s40644-023-00566-7

Ejemplares similares

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells
por: Karschnia, Philipp, et al.
Publicado: (2022)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
por: Stoecklein, Sophia, et al.
Publicado: (2023)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report
por: Rejeski, Kai, et al.
Publicado: (2021)

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
por: Rejeski, Kai, et al.
Publicado: (2023)

Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on (18)F-FDG PET/CT Imaging
por: Winkelmann, Michael, et al.
Publicado: (2021)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
por: Schoeberl, Florian, et al.
Publicado: (2022)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on (18)F-FDG PET/CT
por: Winkelmann, Michael, et al.
Publicado: (2020)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
por: Unterrainer, Marcus, et al.
Publicado: (2020)

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE
por: Blumenberg, V., et al.
Publicado: (2022)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
por: Skalt, Daniela, et al.
Publicado: (2022)

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
por: Daver, Naval, et al.
Publicado: (2021)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
por: Banck, Jan Christoph, et al.
Publicado: (2021)

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
por: Bücklein, Veit, et al.
Publicado: (2023)

Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
por: Mönch, Sebastian, et al.
Publicado: (2023)

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
por: Bücklein, V., et al.
Publicado: (2022)

(18)F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland
por: Holzgreve, Adrien, et al.
Publicado: (2020)

Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
por: Ingenerf, Maria, et al.
Publicado: (2023)

Couples and COVID-19 vaccination: Frequency and reasons for discordance
por: Schmaling, Karen B.
Publicado: (2022)

Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters
por: Ingenerf, Maria, et al.
Publicado: (2022)

Characterizing the Role of the “Triagist”: Reasons for Triage Discordance and Impact on Disposition
por: Amick, Ashley, et al.
Publicado: (2020)

Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients
por: Bücklein, Veit, et al.
Publicado: (2016)

Cytokine release syndrome
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2018)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l29a6ub9dcdnh7946am3ia8emu